Roche was an early ADC pioneer with the approved drugs Kadcyla and Polivy but failed to make further headway.

The federal agency granted accelerated approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no other treatment options.

Pharmaceutical powerhouse AstraZeneca appears to have taken an interest in the company’s London-based partner Mereo BioPharma and may be considering a buyout, according to circulating speculations first reported by The Times UK.

CAR T therapies have revolutionized oncology patient care. But to ensure the often lifesaving benefits of these therapies reach the right patients, life sciences companies must navigate complex decision-making and treatment processes to maximize uptake.

A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030. For context, the top 10 biopharmas in 2021 generated total global sales of $512 billion. In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs.

Powered by the company’s blockbuster checkpoint inhibitor Keytruda, Merck is forecasting the potential of more than 80 new regulatory approvals in oncology through 2028.

Mirati Therapeutics Inc.’s experimental drug that targets a specific genetic mutation helped about one third of a small subset of patients in a clinical trial whose lung cancer had spread to their brains, the company said on Monday.

Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs.

Atreca is reorganizing the company’s workforce in a bid to extend its cash reserves to 2023. 

Shares of Repare Therapeutics soared more than 27 percent in premarket trading on June 2 following the previous day’s announcement of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.